JP2006516030A - Copd及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法 - Google Patents
Copd及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法 Download PDFInfo
- Publication number
- JP2006516030A JP2006516030A JP2006500550A JP2006500550A JP2006516030A JP 2006516030 A JP2006516030 A JP 2006516030A JP 2006500550 A JP2006500550 A JP 2006500550A JP 2006500550 A JP2006500550 A JP 2006500550A JP 2006516030 A JP2006516030 A JP 2006516030A
- Authority
- JP
- Japan
- Prior art keywords
- glutamate
- glu
- copd
- precursor
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 16
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 8
- 201000010099 disease Diseases 0.000 title description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 228
- 229930195712 glutamate Natural products 0.000 claims abstract description 206
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 38
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims abstract description 34
- 239000004223 monosodium glutamate Substances 0.000 claims abstract description 34
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 32
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002243 precursor Substances 0.000 claims abstract description 29
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 21
- 239000004220 glutamic acid Substances 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 230000001154 acute effect Effects 0.000 claims abstract description 14
- 208000017667 Chronic Disease Diseases 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004474 valine Substances 0.000 claims abstract description 13
- 235000013373 food additive Nutrition 0.000 claims abstract description 10
- 239000002778 food additive Substances 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 210000003205 muscle Anatomy 0.000 claims description 25
- 230000001965 increasing effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 10
- 150000004715 keto acids Chemical class 0.000 claims description 10
- 230000037213 diet Effects 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 6
- 239000003375 plant hormone Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000021 stimulant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 101100384805 Homo sapiens ARCN1 gene Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229940049906 glutamate Drugs 0.000 description 58
- 229960003136 leucine Drugs 0.000 description 26
- 230000007423 decrease Effects 0.000 description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
- 230000037406 food intake Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000009885 systemic effect Effects 0.000 description 17
- 229960002989 glutamic acid Drugs 0.000 description 16
- 210000002027 skeletal muscle Anatomy 0.000 description 15
- 230000007306 turnover Effects 0.000 description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000004202 carbamide Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 206010014561 Emphysema Diseases 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 9
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000007918 intramuscular administration Methods 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 230000017854 proteolysis Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229960004295 valine Drugs 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000024977 response to activity Effects 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- -1 amino acid glutamate Chemical class 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000022558 protein metabolic process Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 238000005891 transamination reaction Methods 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004844 protein turnover Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 102000006732 Citrate synthase Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000876841 Gluvia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100338172 Oryza sativa subsp. japonica GLU4 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000004536 heart mitochondria Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- UJKDYMOBUGTJLZ-RUCXOUQFSA-N ksc605q1h Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O UJKDYMOBUGTJLZ-RUCXOUQFSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000015090 marinades Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明によれば、哺乳類、特にヒトのCOPD及び他の急性又は慢性疾患を治療又は予防するのに適した組成物であって、グルタミン酸モノナトリウム塩以外のグルタミン酸塩並びにロイシン、バリン、イソロイシン及びそれらのケト酸からなる群から選択されるグルタミン酸の前駆物質の少なくとも一つを、該グルタミン酸及びその前駆体の総量が少なくとも6グラムの該哺乳類に対する1日用量において含有する組成物が提供される。好ましい態様において該グルタミン酸塩又はグルタミン酸の該前駆体の量は該グルタミン酸塩及びその前駆体の合計で9から20グラムの範囲であり、これはほぼ0.12から0.27 g/kg体重の範囲にある。
この発明のこれら及び他の態様は以下に詳細に説明される。
ここに使用されている用語「グルタミン酸塩」は、特記されない限り、一般的に植物、動物又は食品タンパク質のような天然に存在するタンパク質(通常10 g L-グルタミン酸/100 gタンパク質未満を含む)の中に存在するよりも高いレベルでペプチド中に存在するL-グルタミン酸単位、又は水に溶解して溶液になった又は遊離型の乾燥L-グルタミン酸として食品に加えられた遊離型のL-グルタミン酸のことである。
上記のプロトコールを使用するGLU摂取の代謝の結果は健康若年被検者(平均年齢25歳)及び高齢被検者(平均年齢65歳)及びAmerican Thoracic Societyのガイドライン(3)(努力肺活量1秒率(FEV1)推定の70%未満(平均FEV1:推定の47.5±4.6%、平均年齢65歳)による中等度から重度のCOPDの患者において試験された。定常状態は安定同位元素テクニックを使用してタンパク質及び関連代謝に対するGLU摂取の影響を評価するために必要であったので、GLUの連続投与が行われた。この試験の結果は以下に記述する:
若年ボランティアにおいて20分毎に(2.4%溶液)30 mg GLU/kg体重の連続摂取により約500%の血漿グルタミン酸濃度及び定常状態は120分以内に達成された(図2)。実際にこのプロトコールによるGLU摂取は血漿中のGLU濃度を速やかに有意な増加に導いた。これはCOPD患者及び対応する年齢の(高齢)健康被検者における後の試験において確認された。GLU摂取は両群における血漿GLUレベルの有意な増加を生じた。興味深いことに、GLU増加レベルは対照群におけるよりもCOPD群において有意に低かった(図3)。このことは、グルタミン酸の取り込み(内臓領域及び/又は末梢)がCOPDにおいて促進されていることを示唆する。
この血漿GLU増加が実際にGLU摂取による血漿中GLU出現の増加によるものであるか否かを試験するために、若年被検者において安定同位元素法を使用して血漿中のGLU出現をGLU補充の前及びその間に測定した。血漿プール中のGLU出現は摂取の開始後急速に増加し、そして1.5時間以内に定常状態に達した(図5)。
若年健康ボランティアにおいて、安定同位元素法を使用してグルタミン酸補充の間の全身のタンパク質及び3-メチルヒスチジンのターンオーバーを測定した。全身タンパク質分解速度はGLU補充の間有意に減少した(図6)。全身タンパク質代謝に対する筋肉の寄与を明らかにするために、筋原繊維のタンパク質分解速度(3-メチルヒスチジンターンオーバー)を同時に測定した。3-メチルヒスチジン分解速度もGLU摂取の間減少する(図7)ように思われ、全身レベルのみならず筋肉レベルに対してもGLUの同化作用を示した。
COPD被検者及び年齢マッチ対照被検者において30.0 mg GLU/kg体重の2.4%溶液、同モル量の対照飲料(29.8 mgグルタミン/kg体重)又は同量の水を摂取した後20分毎にその後4時間、尿素濃度を測定した。この3飲料は異なる日に、同様な試験プロトコールを使用して無作為化した順序で試験された。健康対照群及びCOPD群の両者において、ベースライン値に比較して、血漿尿素はGLU摂取後直ちに減少したが、GLN摂取後には増加した(図9a及びb)。GLU摂取の間の血漿尿素レベルの減少は少なくとも1時間で回復するまで安静時及び運動時にも存在した。尿素レベルの減少は、摂取された窒素は体の中に残留しそしてグルタミンの場合のように浪費されないことを示している。これはCOPD及び健康対照においてグルタミン酸がタンパク質同化を誘導した以前の観察と一致する。
吸収後の状態において、ロイシントレーサーにより測定された全身ロイシンターンオーバーは健康な年齢マッチ対照に比較してCOPD患者において安静時に増加した。COPDおよび対照被検者の両者において、グルタミン酸摂取はタンパク質ターンオーバーと関係なく全身ロイシンターンオーバーの減少を誘発した(図11)。
運動時のCOPD群においてグルタミン酸摂取は水を摂取した場合よりも少ない血漿乳酸濃度の増加を生じた(図13)。これは、グルタミン酸摂取が運動に対する乳酸反応を減少させそしてこのようにしてこの患者群において筋肉疲労の発生を減少/遅延させることを示している。
実験において、グルタミン酸の摂取は通常4〜6時間の間に6〜7 g/時間の程度であり、これは合計摂取量は少なくとも30グラムであることを意味する。したがってこの摂取量はMSGの推定1日摂取量の30倍以上である。しかし、GLU摂取の間及びその後にCOPD患者又は年齢マッチ健康対照被検者の一人も(中華料理店症候群による症状を含む)副作用を示さなかった。
引用文献
Claims (11)
- グルタミン酸モノナトリウム以外のグルタミン酸塩並びに及びロイシン、バリン、イソロイシン、及びそれらのケト酸からなる群から選択されるグルタミン酸の前駆体の少なくとも一つを、該グルタミン酸塩及びその前駆体の合計で6グラムの哺乳類に対する1日投与量において含む、哺乳類、特にヒトのCOPD及びその他の急性又は慢性の疾患の治療又は予防に適する組成物。
- グルタミン酸モノナトリウム以外のグルタミン酸塩及びロイシン、バリン、イソロイシン、及びそのケト酸からなる群から選択されるグルタミン酸の前駆体の少なくとも一つを、該グルタミン酸塩及びその前駆体の合計で9から20グラムの間の前記哺乳類に対する1日投与量において含む、請求項1に記載の組成物。
- グルタミン酸レベルを持続的に増加させるために定期的に投与するために該グルタミン酸塩又はその前駆体の量が3グラムまでの用量に分割されているダイエット食品添加物である請求項1又は2に記載の組成物。
- グルタミン酸レベルの持続的増加を達成するために定期的に投与するために該グルタミン酸塩又はその前駆体の量が3グラムまでの単位投与量に分割されており、さらに医薬として受容しうる担体を含んでいる医薬組成物である、請求項1又は2に記載の組成物。
- 哺乳類、特にヒトのCOPD及びそのほかの急性又は慢性疾患の治療又は予防のための医薬品の調製における、グルタミン酸モノナトリウム以外のグルタミン酸塩並びにロイシン、バリン、イソロイシン、及びそれらのケト酸からなる群から選択されたグルタミン酸の前駆体の少なくとも一つの使用であって、該医薬品が、該医薬品の有効成分の少なくとも6グラムの1日用量を達成する単位用量形態に製剤化されている、使用。
- 前記医薬品が、該医薬品の有効成分の9から20グラムの間の範囲の1日用量を達成する単位用量形態に製剤化されている請求項5に記載の使用。
- 経口又は非経口投与用に製剤化されている請求項4に記載の医薬組成物、又は請求項5若しくは6に記載の使用。
- グルタミン酸レベルの持続的増加を達成するために製剤化された請求項4に記載された医薬組成物、又は請求項5若しくは6に記載の使用。
- 前記医薬品が、刺激剤、ホルモン、該ホルモンのアナログ、植物ホルモン、該植物ホルモンのアナログ、及び抗酸化物質の群から選択される1以上の物質をさらに含んでいる請求項5から8のいずれかに記載の使用。
- グルタミン酸モノナトリウム以外のグルタミン酸塩並びにロイシン、バリン、イソロイシン、及びそのケト酸からなる群から選択されたグルタミン酸の前駆体の少なくとも一つの治療有効量を哺乳類に投与する、哺乳類、特にヒトのCOPD及びその他の急性又は慢性疾患を予防又は治療する方法。
- ヒトの体、特に筋肉におけるグルタミン酸レベルを回復又は増加させるための食品添加物又は予防組成物の調製における、グルタミン酸モノナトリウム以外のグルタミン酸塩並びにロイシン、バリン、イソロイシン、及びそのケト酸からなる群から選択されるグルタミン酸の前駆体の少なくとも一つの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03075179 | 2003-01-10 | ||
PCT/EP2004/000151 WO2004062656A1 (en) | 2003-01-10 | 2004-01-12 | Compositions and methods for improving the condition of patients suffering from copd and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006516030A true JP2006516030A (ja) | 2006-06-15 |
Family
ID=32479932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006500550A Pending JP2006516030A (ja) | 2003-01-10 | 2004-01-12 | Copd及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060173079A1 (ja) |
EP (1) | EP1585512A1 (ja) |
JP (1) | JP2006516030A (ja) |
KR (1) | KR20050107573A (ja) |
CN (1) | CN1747728A (ja) |
WO (1) | WO2004062656A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013066410A (ja) * | 2011-09-21 | 2013-04-18 | Terumo Corp | 分岐鎖アミノ酸を含有する焼菓子 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006049286A1 (ja) * | 2004-11-02 | 2008-05-29 | 味の素株式会社 | アレルギー性疾患予防・治療剤 |
IT1397023B1 (it) * | 2009-11-27 | 2012-12-20 | Professional Dietetics Srl | Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva |
US20150359771A1 (en) * | 2013-01-15 | 2015-12-17 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
US10234448B2 (en) * | 2015-10-06 | 2019-03-19 | The Texas A&M University System | Methods for diagnosing impaired absorption of amino acids, monosaccharides and fatty acids |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179080A (en) * | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
DE69723812D1 (de) * | 1996-01-09 | 2003-09-04 | Riken Wako | Aminosäurezusammensetzungen |
EP1294903B1 (en) * | 2000-06-13 | 2008-05-07 | Bayer HealthCare AG | Regulation of human transmembrane serine protease |
-
2004
- 2004-01-12 EP EP04701359A patent/EP1585512A1/en not_active Withdrawn
- 2004-01-12 JP JP2006500550A patent/JP2006516030A/ja active Pending
- 2004-01-12 WO PCT/EP2004/000151 patent/WO2004062656A1/en active Application Filing
- 2004-01-12 US US10/542,120 patent/US20060173079A1/en not_active Abandoned
- 2004-01-12 CN CNA2004800040677A patent/CN1747728A/zh active Pending
- 2004-01-12 KR KR1020057013235A patent/KR20050107573A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013066410A (ja) * | 2011-09-21 | 2013-04-18 | Terumo Corp | 分岐鎖アミノ酸を含有する焼菓子 |
Also Published As
Publication number | Publication date |
---|---|
KR20050107573A (ko) | 2005-11-14 |
EP1585512A1 (en) | 2005-10-19 |
WO2004062656A1 (en) | 2004-07-29 |
US20060173079A1 (en) | 2006-08-03 |
CN1747728A (zh) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2512236B1 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
EP1089726B1 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
CA2711809A1 (en) | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly | |
TW200410680A (en) | Nutritiona compositions | |
JP3906716B2 (ja) | 耐糖能異常用薬剤 | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
JP2004505056A (ja) | 心血管の機能を向上する為の組成物及び方法 | |
JPH06510769A (ja) | 低血圧症と関連疾患の治療のためのアミノ酸非経口製剤 | |
JP2006516030A (ja) | Copd及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法 | |
JP2015131849A (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
JP4715423B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
JP6112767B2 (ja) | 血液中の尿酸値を低下させるための組成物 | |
KR20070085961A (ko) | 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도 | |
RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
JPH11171763A (ja) | 肝疾患治療剤 | |
CA3106895A1 (en) | Nutritional compositions for enhancement of muscle performance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070104 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100521 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100823 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100830 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110121 |